China's National Medical Products Administration (NMPA) has approved Hong Kong-based Harbour BioMed's Investigational New Drug (IND) application for HBM4003, the next generation anti-CTLA-4 antibody in combination with PD-1 antibody/chemotherapy intended for the treatment of patients with advanced NSCLC and solid tumours, it was reported on Thursday.
The study is to assess the safety, tolerability, PK/PD, and anti-tumour activity of the product in combination with PD-1 antibody, with or without chemotherapy, in subjects with advanced NSCLC and other solid tumours.
The product is the fully human anti-CTLA-4 monoclonal heavy chain only antibody generated from Harbour Mice. It has already received US FDA and China NMPA IND approvals of the mono therapy and another combination therapy in China. It has completed patient dosing in several patients in its ongoing phase I study in Australia.
Shield Therapeutics wins FDA approval to expand ACCRUFeR use to adolescents
ECO Animal Health Group secures EU approval for ECOVAXXIN MS
Hansa Biopharma submits imlifidase Biologics License Application to FDA
T-MAXIMUM Pharmaceutical receives IND approval to start Phase II trial of MT027 for rGBM
Alvotech and Teva secure US launch date for Eylea biosimilar AVT06
Egetis initiates rolling US NDA for Emcitate in MCT8 deficiency
Abbott's Amplatzer Piccolo Delivery System receives US FDA clearance and CE Mark
Amphix Bio announces initial closing of USD12.5m seed financing round
BiBBInstruments reports additional US orders during targeted EndoDrill GI launch
Sanofi's efdoralprin alfa receives EU orphan designation for AATD-related emphysema
Black Buffalo partners with Sanova to support regulatory strategy and scientific innovation
Nicox completes key data package for NCX 470 NDA submissions
Immusoft's ISP-002 granted US FDA Orphan Drug Designation in MPS II
Orphan Therapeutics Accelerator signs MoU with Fondazione Telethon
Bioretec wins FDA breakthrough status for biodegradable orthopaedic DrillPin